19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace

 

 

 

 


powered by centersite dot net
Women's Health
Resources
Basic InformationLatest News
Low-Fat Diet Could Be a Weapon Against Breast CancerAHA News: Why Are Women With Diabetes at Greater Risk for Poor Heart Health?Routine Use of Antibiotics May Help After Complicated Vaginal Birth: StudyAre You Running Short on Iron?Weight Before Pregnancy Most Important to Risk for ComplicationsIs AI a New Weapon in Breast Cancer Detection?Many Pregnancy-Related Maternal Deaths Occur Months After Delivery: CDCQuitting Smoking Helps Shield Women From Bladder Cancer: StudyThe Surprising Lead Cause of Death for Pregnant WomenBreast Surgeons' Group Issues New Mammogram GuidelinesHow to Know If Your PMS Is Something More SeriousHealth Tip: What to Expect From a Gynecologist VisitMale-Hormone Gene May Help Cause Polycystic Ovary SyndromeWhat Price Beauty for Women? Far More Than for MenSnoring Not Just a Male ProblemMany Women With Heart Disease Falling Short on ExerciseMost States Restrict Pregnant Women's Advance Directives: StudyStudy Supports Radiation for Early, Hormone-Driven Breast CancerLong-Term Antibiotic Use May Up Women's Odds for Heart Trouble1 in 9 U.S. Women Drink During Pregnancy, and Numbers Are RisingNot All Cervical Cancer Rates Are DecliningHPV Vaccine Driving Down Cervical Pre-Cancer RatesAHA News: Here's How Middle-Aged People -- Especially Women -- Can Avoid a Heart AttackC-Section Infection Risk Higher for Moms on Medicaid: StudyLegacy of Gulf War Deployment: Higher Risk of Minor Birth DefectsFDA Halts All Sales of Pelvic Mesh Products Tied to Injuries in WomenCelebrity 'Fat-Shaming' Affects All Women, Study FindsFDA Orders Label Warning on Alcohol Use With 'Female Viagra'Could Very Low 'Bad' Cholesterol Bring Stroke Danger?Herbals in Pregnancy May Endanger Mom, BabyEvenity Approved for Osteoporotic WomenWhen Do Women Need a Mammogram? New Guideline Tries to ClarifyMore Evidence HPV Vaccine Cuts Cervical Cancer RateBlack Women in the U.S. Still Missing Out on Heart CareIs That Medication Safe When Breastfeeding?Birth Control Pills May Protect Against Most Serious Ovarian Cancer: StudySurgery May Boost Outcomes in Common Form of Advanced Breast CancerHealth Tip: Treating EndometriosisFewer Periods May Mean Higher Dementia RiskDual-Drug Therapy May Boost Odds Against a Tough Breast CancerFDA Says Breast Density Must Be Reported to Women During MammogramsAHA News: Stressful Life Events Tied to Heart Disease in Older Black WomenLess Invasive Fibroid Treatment May Work as Well as SurgeryAffordable Care Act Brought Big Benefits to Women: StudyIs There a Safer Choice Than Opioids After a C-Section?Three Clues to Raised Risk of MiscarriageFDA Approves First Drug for Postpartum DepressionWhat Works Best for Women Struggling With a Leaky Bladder?Even Housework, Gardening Can Help an Older Woman's HeartAHA News: Black Woman in Their 50s Face Especially High Stroke Risk
Questions and AnswersVideosLinksBook ReviewsSelf-Help Groups
Related Topics

Wellness and Personal Development
Mental Disorders

Experimental Drug Helps Women With Deadly Type of Breast Cancer

HealthDay News
by By Steven ReinbergHealthDay Reporter
Updated: Feb 20th 2019

new article illustration

WEDNESDAY, Feb. 20, 2019 (HealthDay News) -- An experimental drug has shown promise in extending the lives of women suffering from a particularly aggressive and deadly type of breast cancer, according to the results of a phase 2 trial.

Right now, the standard treatment of chemotherapy for metastatic triple-negative breast cancer has not been very effective. That might change with the new drug, called sacituzumab govitecan, which combines an antibody with a chemotherapy drug to better target cancer cells.

In the trial, funded by the drug's maker, about a third of the patients responded to treatment and the effect lasted up to eight months, said study senior author Dr. Kevin Kalinsky.

"These patients had a significant reduction of their cancer," he added. "This is an exciting new therapeutic."

About 50 percent had some response and saw a slowing of cancer progression for about five months, he noted.

Kalinsky, an oncologist at the Irving Medical Center at New York-Presbyterian-Columbia University, also noted: "This is a patient population where we really need new therapeutics."

Triple-negative breast cancer represents about 15 percent of all breast cancer and is most often seen in young women and black women, although why it affects these women isn't known, according to Dr. J. Leonard Lichtenfeld, the interim chief medical officer at the American Cancer Society.

The cancer is different from other breast cancers because tumor cells don't have protein HER2 (human epidermal growth factor receptor 2), estrogen receptors or progesterone receptors, which means that hormonal treatment or drugs that target HER2 are ineffective. Chemotherapy shrinks or slows its progress in only about 10 percent to 15 percent of these patients, and the effect only lasts about two to three months, the researchers said.

Survival for women with metastatic triple-negative breast cancer is around a year, and that has not changed for 20 years, they noted.

In this phase 2 trial, 108 women who had failed treatment with other drugs were treated with sacituzumab govitecan. The drug combines an antibody to the Trop-2 antigen, which is found on most breast cancer cells, with the chemotherapy drug irinotecan.

When the antibody latches onto the Trop-2 molecules of the cancer cells, the drug is released within cells and into the areas of the tumor. This targeted delivery allows the chemotherapy drug to reach cancer cells and helps reduce the toxic effect of the drug to healthy cells, the researchers said.

The trial lasted from June 2013 to February 2017 and was funded by New Jersey-based Immunomedics.

Patients were given the drug for as long as they benefited from treatment, and eight women were still on the drug as of December 2017. The average time of treatment was more than five months, which was longer than the average 2.5 months with patients' other treatments, the researchers found.

Some of the drug's side effects included nausea, diarrhea and a drop in white blood cells. Researchers said these symptoms were manageable.

The drug is not yet available, Kalinsky said. A phase 3 trial comparing sacituzumab govitecan with other treatments for triple-negative breast cancer is now underway.

"This is a step forward for women where there were not any real treatment options," said Lichtenfeld, who was not involved with the study. "It was not a cure -- we still have a long way to go."

He added that the drug might be more effective if it were given earlier, when the cancer was still confined to the breast.

"Even with these results, however, it represents a better outcome than any of the treatments used in this form of breast cancer," Lichtenfeld said.

The report was published Feb. 20 in the New England Journal of Medicine.

More information

The American Cancer Society offers more information on breast cancer.